Bing

SEARCH HISTORY

Monday sure didn’t do anything to disappoint those expectations for pharmaceuticals, adding upwards of $10 billion to the sector’s M&A tally. Roche contributed by far the least to total deal value, while anyone holding QCOR stock should be smiling.
Investor Place · ByDan Burrows · 4/7/2014
So unless Questcor Pharmaceuticals Inc sees its shares decline ... For other put options contract ideas at the various different available expirations, visit the QCOR Stock Options page of StockOptionsChannel.com.
Forbes · 8/29/2013
ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial. Highlights from the ratings report include: QCOR's very impressive revenue growth greatly …
The Street · 10/19/2012
More from Bing News
Upcoming Aetna Policy Update has little downside, but lots of potential upside. Getting long QCOR now appears to make sense as the next major catalyst is Aetna's anticipated Policy Update on October 13th, which everyone expects will remain negative …
Reuters · 10/2/2012
Acthar is not a first-line therapy for MS or Nephrotic Syndrome ... Our view is that the sell-off is overdone and that a fair price for QCOR stock lies somewhere between the recent lows around $18 and previous highs of $50. Should QCOR's sales trajectory ...
Seeking Alpha · 10/18/2012
Questcor Pharmaceuticals, Inc. (QCOR) was a big mover last session, as the company saw its shares shoot up nearly 19% on the day. This surge can be attributable to solid volume with far more shares changing hands than in a normal session. This broke …
Yahoo Finance · 4/8/2014
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) investors ... and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300) This is a FREE report from Insider Monkey. Credit Card is NOT required.
INSIDER MONKEY · 8/27/2013
Questcor Pharmaceuticals, Inc. (QCOR) is going all crazy'n stuff today following kick-butt quarter. Robust sales for Acthar put to rest worries that reimbursement issues for newer uses of the drug might restrict sales, and the stock is up more than 30% as ...
istock Analyst · 7/31/2013
as Citron has taken the extra steps necessary to uncover the "mystery" active ingredients in one of the most controversial drugs on the marketplace. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has been a battleground stock for years. Bulls have stood ...
Value Walk · 2/28/2014
Questcor Pharmaceuticals, Inc. ( QCOR) was a big mover last session, as the company saw its shares shoot up nearly 19% on the day. This surge can be attributable to solid volume with far more shares changing hands than in a normal session. This …
NASDAQ · 4/8/2014